Reduction in Vaccine-Type Human Papillomavirus Prevalence Among Women in the United States, 2009-2012.
Between 2009 and 2012, the proportion of young women in the United States completing the human papillomavirus (HPV) vaccine doubled. To understand how quickly this increased uptake is affecting women in the United States, we evaluated the prevalence of vaccine-type (VT) HPV strains among young women in national data sets from 2009-2010 and 2011-2012. Among 18-26-year-old women, the prevalence of VT HPV decreased markedly over a short interval, from 15.4% in 2009-2010 to 8.5% in 2011-2012 (prevalence ratio, 0.51; 95% confidence interval, .28-.92), and the prevalence of high-risk VT HPV decreased from 13.1% to 6.5% (0.46; .25-.86). Reductions in HPV-related diseases will probably follow.
Center for Interdisciplinary Research in Women's Health.|Department of Obstetrics & Gynecology, The University of Texas Medical Branch, Galveston.
Abbey B
AB
Berenson
Center for Interdisciplinary Research in Women's Health.
Tabassum Haque
TH
Laz
Center for Interdisciplinary Research in Women's Health.
Mahbubur
M
Rahman
D000293:Adolescent; D000328:Adult; D003430:Cross-Sectional Studies; D005260:Female; D005838:Genotype; D006801:Humans; D008875:Middle Aged; D027383:Papillomaviridae / Q000145:classification* / Q000235:genetics / Q000302:isolation & purification*; D030361:Papillomavirus Infections / Q000453:epidemiology* / Q000821:virology*; D053918:Papillomavirus Vaccines / Q000276:immunology*; D015995:Prevalence; D014481:United States / Q000453:epidemiology; D055815:Young Adult
D053918:Papillomavirus Vaccines
HPV vaccine; human papillomavirus; prevalence; young adults